4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

NCTID	NCT05197270 (View at clinicaltrials.gov)
Description	Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding. (Show More)
Development Status	Active
Indication	Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
Disease Ontology Term	DOID:10871
Compound Name	4D-150
Sponsor	4D Molecular Therapeutics
Funder Type	Industry
Recruitment Status	Recruiting (Click here for study contact information)
Enrollment Count	215 (ESTIMATED)
Results Posted	Not Available

Target Gene/Variant	Anti-VEGF
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Genetic delivery of therapeutic protein
Route of Administration	Intravitreal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV
Editor Type	none
Dose 1	1E10 vg/eye
Dose 2	3E10 vg/eye (planned phase 3 dose)
Dose 3
Dose 4
Dose 5

No.of Trial Sites	24
Locations	Puerto Rico,United States

Has US IND	True
FDA Designations	Regenerative Medicine Advanced Therapy
Recent Updates	Phase III trial to begin Q1 2025